Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients

Απλή σελίδα τεκμηρίου
dc.contributor.authorTsouchnikas, I.en
dc.contributor.authorDounousi, E.en
dc.contributor.authorPapakonstantinou, S.en
dc.contributor.authorIoannou, K.en
dc.contributor.authorKelesidis, A.en
dc.contributor.authorKotzadamis, N.en
dc.contributor.authorXanthopoulou, K.en
dc.contributor.authorTsakiris, D.en
dc.date.accessioned2015-11-24T19:33:16Z
dc.date.available2015-11-24T19:33:16Z
dc.identifier.issn1440-1797-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23518
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectC-Reactive Protein/analysisen
dc.subjectCholesterol, LDL/blooden
dc.subjectErythropoietin/*therapeutic useen
dc.subjectFemaleen
dc.subjectHeptanoic Acids/*therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectPyrroles/*therapeutic useen
dc.subject*Renal Dialysisen
dc.titleBeneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patientsen
heal.abstractAIM: To evaluate the effect of atorvastatin on erythropoietin responsiveness and whether this effect is mediated by C-reactive protein (CRP) reduction in prevalent dyslipidemic, haemodialysis patients. METHODS: We studied prospectively 33 stable, iron-repleted haemodialysis patients with low-density lipoprotein cholesterol (LDL) > or =2.58 mmol/L, who received 20 mg atorvastatin aiming to achieve the target of LDL <2.58 mmol/L, over a period of 9 months. Twenty-five patients completed the study, 15 men, with mean age 66.1 +/- 8.2 years. The duration of haemodialysis was 56.6 +/- 63.1 months and 5/25 patients were diabetics. Total serum cholesterol, triglycerides, high-density lipoprotein cholesterol, LDL, haemoglobin, albumin, intact parathyroid hormone, serum iron, ferritin, total iron binding capacity, CRP and weekly dose of erythropoietin/body weight/haemoglobin were analysed. RESULTS: Twenty of the 25 patients (80%) achieved the goal of LDL <2.58 mmol/L. There was a significant decrease in total cholesterol (5.77 +/- 0.88 to 4.16 +/- 0.96 mmol/L, P < 0.001) and LDL (3.59 +/- 0.77 to 1.94 +/- 0.77 mmol/L, P < 0.001). Haemoglobin increased from 121 +/- 11 to 126 +/- 7 g/L (P < 0.05), while weekly dose of erythropoietin/body weight/haemoglobin decreased significantly from 8.34 +/- 3.70 to 7.87 +/- 3.11 IU/kg per haemoglobin (P < 0.05). CRP decreased not significantly from 7.0 +/- 6.1 to 4.5 +/- 2.2 mg/L. CONCLUSION: Dyslipidemia of haemodialysis patients was treated safely and effectively with atorvastatin, but a fifth of the patients failed to achieve the therapeutic target. Statin therapy resulted in a significant increase of haemoglobin levels and improvement of erythropoietin responsiveness without a significant reduction in CRP levels, suggesting that the beneficial effect of statins on erythropoietin responsiveness may be driven by a mechanism other than CRP reduction.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1111/j.1440-1797.2009.01084.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19422526-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1440-1797.2009.01084.x/asset/j.1440-1797.2009.01084.x.pdf?v=1&t=h0ul4dos&s=c9a7a07acc74ae13c899051be2973569697b79ef-
heal.journalNameNephrology (Carlton)en
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ